Discovery of Potent and Selective p53-MDM2 Protein–Protein Interaction Inhibitors as Anticancer Drugs

As a result of our persistent efforts to discover novel inhibitors of the p53-MDM2 protein–protein interaction useful for the treatment of cancer, the potent and selective MDM2 inhibitors NVP-CGM097 and NVP-HDM201 with excellent in vitro and in vivo profile were selected as clinical candidates and a...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Philipp Holzer [verfasserIn]

Format:	E-Artikel
Sprache:	Deutsch ; Englisch ; Französisch

Erschienen:	2017

Schlagwörter:	Clinical trial Hdm2 Inhibitor Mdm2 Nvp-cgm097 Nvp-hdm201

Übergeordnetes Werk:	In: CHIMIA - Swiss Chemical Society, 2020, 71(2017), 10
Übergeordnetes Werk:	volume:71 ; year:2017 ; number:10

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc Journal toc

DOI / URN:	10.2533/chimia.2017.716

Katalog-ID:	DOAJ046037047

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ046037047
003	DE-627
005	20230308102142.0
007	cr uuu---uuuuu
008	230227s2017 xx \|\|\|\|\|o 00\| \|\|ger c
024	7		\|a 10.2533/chimia.2017.716 \|2 doi
035			\|a (DE-627)DOAJ046037047
035			\|a (DE-599)DOAJ1e830f523fe54d70b46c9def3403fa01
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a ger \|a eng \|a fre
050		0	\|a QD1-999
100	0		\|a Philipp Holzer \|e verfasserin \|4 aut
245	1	0	\|a Discovery of Potent and Selective p53-MDM2 Protein–Protein Interaction Inhibitors as Anticancer Drugs
264		1	\|c 2017
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a As a result of our persistent efforts to discover novel inhibitors of the p53-MDM2 protein–protein interaction useful for the treatment of cancer, the potent and selective MDM2 inhibitors NVP-CGM097 and NVP-HDM201 with excellent in vitro and in vivo profile were selected as clinical candidates and are currently in phase 1 clinical development. This short review article provides a summary of the program history, the applied pharmacophore model and the discovery story of these novel p53-MDM2 inhibitor investigational drugs.
650		4	\|a Clinical trial
650		4	\|a Hdm2
650		4	\|a Inhibitor
650		4	\|a Mdm2
650		4	\|a Nvp-cgm097
650		4	\|a Nvp-hdm201
653		0	\|a Chemistry
773	0	8	\|i In \|t CHIMIA \|d Swiss Chemical Society, 2020 \|g 71(2017), 10 \|w (DE-627)480660301 \|w (DE-600)2179192-2 \|x 26732424 \|7 nnns
773	1	8	\|g volume:71 \|g year:2017 \|g number:10
856	4	0	\|u https://doi.org/10.2533/chimia.2017.716 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/1e830f523fe54d70b46c9def3403fa01 \|z kostenfrei
856	4	0	\|u https://www.chimia.ch/chimia/article/view/1668 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/0009-4293 \|y Journal toc \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2673-2424 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 71 \|j 2017 \|e 10

Indexfelder

author_variant	p h ph
matchkey_str	article:26732424:2017----::icvroptnadeetvp3d2rtipoenneatoihb
hierarchy_sort_str	2017
callnumber-subject-code	QD
publishDate	2017
allfields	10.2533/chimia.2017.716 doi (DE-627)DOAJ046037047 (DE-599)DOAJ1e830f523fe54d70b46c9def3403fa01 DE-627 ger DE-627 rakwb ger eng fre QD1-999 Philipp Holzer verfasserin aut Discovery of Potent and Selective p53-MDM2 Protein–Protein Interaction Inhibitors as Anticancer Drugs 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier As a result of our persistent efforts to discover novel inhibitors of the p53-MDM2 protein–protein interaction useful for the treatment of cancer, the potent and selective MDM2 inhibitors NVP-CGM097 and NVP-HDM201 with excellent in vitro and in vivo profile were selected as clinical candidates and are currently in phase 1 clinical development. This short review article provides a summary of the program history, the applied pharmacophore model and the discovery story of these novel p53-MDM2 inhibitor investigational drugs. Clinical trial Hdm2 Inhibitor Mdm2 Nvp-cgm097 Nvp-hdm201 Chemistry In CHIMIA Swiss Chemical Society, 2020 71(2017), 10 (DE-627)480660301 (DE-600)2179192-2 26732424 nnns volume:71 year:2017 number:10 https://doi.org/10.2533/chimia.2017.716 kostenfrei https://doaj.org/article/1e830f523fe54d70b46c9def3403fa01 kostenfrei https://www.chimia.ch/chimia/article/view/1668 kostenfrei https://doaj.org/toc/0009-4293 Journal toc kostenfrei https://doaj.org/toc/2673-2424 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 71 2017 10
spelling	10.2533/chimia.2017.716 doi (DE-627)DOAJ046037047 (DE-599)DOAJ1e830f523fe54d70b46c9def3403fa01 DE-627 ger DE-627 rakwb ger eng fre QD1-999 Philipp Holzer verfasserin aut Discovery of Potent and Selective p53-MDM2 Protein–Protein Interaction Inhibitors as Anticancer Drugs 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier As a result of our persistent efforts to discover novel inhibitors of the p53-MDM2 protein–protein interaction useful for the treatment of cancer, the potent and selective MDM2 inhibitors NVP-CGM097 and NVP-HDM201 with excellent in vitro and in vivo profile were selected as clinical candidates and are currently in phase 1 clinical development. This short review article provides a summary of the program history, the applied pharmacophore model and the discovery story of these novel p53-MDM2 inhibitor investigational drugs. Clinical trial Hdm2 Inhibitor Mdm2 Nvp-cgm097 Nvp-hdm201 Chemistry In CHIMIA Swiss Chemical Society, 2020 71(2017), 10 (DE-627)480660301 (DE-600)2179192-2 26732424 nnns volume:71 year:2017 number:10 https://doi.org/10.2533/chimia.2017.716 kostenfrei https://doaj.org/article/1e830f523fe54d70b46c9def3403fa01 kostenfrei https://www.chimia.ch/chimia/article/view/1668 kostenfrei https://doaj.org/toc/0009-4293 Journal toc kostenfrei https://doaj.org/toc/2673-2424 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 71 2017 10
allfields_unstemmed	10.2533/chimia.2017.716 doi (DE-627)DOAJ046037047 (DE-599)DOAJ1e830f523fe54d70b46c9def3403fa01 DE-627 ger DE-627 rakwb ger eng fre QD1-999 Philipp Holzer verfasserin aut Discovery of Potent and Selective p53-MDM2 Protein–Protein Interaction Inhibitors as Anticancer Drugs 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier As a result of our persistent efforts to discover novel inhibitors of the p53-MDM2 protein–protein interaction useful for the treatment of cancer, the potent and selective MDM2 inhibitors NVP-CGM097 and NVP-HDM201 with excellent in vitro and in vivo profile were selected as clinical candidates and are currently in phase 1 clinical development. This short review article provides a summary of the program history, the applied pharmacophore model and the discovery story of these novel p53-MDM2 inhibitor investigational drugs. Clinical trial Hdm2 Inhibitor Mdm2 Nvp-cgm097 Nvp-hdm201 Chemistry In CHIMIA Swiss Chemical Society, 2020 71(2017), 10 (DE-627)480660301 (DE-600)2179192-2 26732424 nnns volume:71 year:2017 number:10 https://doi.org/10.2533/chimia.2017.716 kostenfrei https://doaj.org/article/1e830f523fe54d70b46c9def3403fa01 kostenfrei https://www.chimia.ch/chimia/article/view/1668 kostenfrei https://doaj.org/toc/0009-4293 Journal toc kostenfrei https://doaj.org/toc/2673-2424 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 71 2017 10
allfieldsGer	10.2533/chimia.2017.716 doi (DE-627)DOAJ046037047 (DE-599)DOAJ1e830f523fe54d70b46c9def3403fa01 DE-627 ger DE-627 rakwb ger eng fre QD1-999 Philipp Holzer verfasserin aut Discovery of Potent and Selective p53-MDM2 Protein–Protein Interaction Inhibitors as Anticancer Drugs 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier As a result of our persistent efforts to discover novel inhibitors of the p53-MDM2 protein–protein interaction useful for the treatment of cancer, the potent and selective MDM2 inhibitors NVP-CGM097 and NVP-HDM201 with excellent in vitro and in vivo profile were selected as clinical candidates and are currently in phase 1 clinical development. This short review article provides a summary of the program history, the applied pharmacophore model and the discovery story of these novel p53-MDM2 inhibitor investigational drugs. Clinical trial Hdm2 Inhibitor Mdm2 Nvp-cgm097 Nvp-hdm201 Chemistry In CHIMIA Swiss Chemical Society, 2020 71(2017), 10 (DE-627)480660301 (DE-600)2179192-2 26732424 nnns volume:71 year:2017 number:10 https://doi.org/10.2533/chimia.2017.716 kostenfrei https://doaj.org/article/1e830f523fe54d70b46c9def3403fa01 kostenfrei https://www.chimia.ch/chimia/article/view/1668 kostenfrei https://doaj.org/toc/0009-4293 Journal toc kostenfrei https://doaj.org/toc/2673-2424 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 71 2017 10
allfieldsSound	10.2533/chimia.2017.716 doi (DE-627)DOAJ046037047 (DE-599)DOAJ1e830f523fe54d70b46c9def3403fa01 DE-627 ger DE-627 rakwb ger eng fre QD1-999 Philipp Holzer verfasserin aut Discovery of Potent and Selective p53-MDM2 Protein–Protein Interaction Inhibitors as Anticancer Drugs 2017 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier As a result of our persistent efforts to discover novel inhibitors of the p53-MDM2 protein–protein interaction useful for the treatment of cancer, the potent and selective MDM2 inhibitors NVP-CGM097 and NVP-HDM201 with excellent in vitro and in vivo profile were selected as clinical candidates and are currently in phase 1 clinical development. This short review article provides a summary of the program history, the applied pharmacophore model and the discovery story of these novel p53-MDM2 inhibitor investigational drugs. Clinical trial Hdm2 Inhibitor Mdm2 Nvp-cgm097 Nvp-hdm201 Chemistry In CHIMIA Swiss Chemical Society, 2020 71(2017), 10 (DE-627)480660301 (DE-600)2179192-2 26732424 nnns volume:71 year:2017 number:10 https://doi.org/10.2533/chimia.2017.716 kostenfrei https://doaj.org/article/1e830f523fe54d70b46c9def3403fa01 kostenfrei https://www.chimia.ch/chimia/article/view/1668 kostenfrei https://doaj.org/toc/0009-4293 Journal toc kostenfrei https://doaj.org/toc/2673-2424 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 71 2017 10
language	German English French
source	In CHIMIA 71(2017), 10 volume:71 year:2017 number:10
sourceStr	In CHIMIA 71(2017), 10 volume:71 year:2017 number:10
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Clinical trial Hdm2 Inhibitor Mdm2 Nvp-cgm097 Nvp-hdm201 Chemistry
isfreeaccess_bool	true
container_title	CHIMIA
authorswithroles_txt_mv	Philipp Holzer @@aut@@
publishDateDaySort_date	2017-01-01T00:00:00Z
hierarchy_top_id	480660301
id	DOAJ046037047
language_de	deutsch englisch franzoesisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ046037047</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308102142.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2017 xx \|\|\|\|\|o 00\| \|\|ger c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2533/chimia.2017.716</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ046037047</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ1e830f523fe54d70b46c9def3403fa01</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">ger</subfield><subfield code="a">eng</subfield><subfield code="a">fre</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QD1-999</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Philipp Holzer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Discovery of Potent and Selective p53-MDM2 Protein–Protein Interaction Inhibitors as Anticancer Drugs</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">As a result of our persistent efforts to discover novel inhibitors of the p53-MDM2 protein–protein interaction useful for the treatment of cancer, the potent and selective MDM2 inhibitors NVP-CGM097 and NVP-HDM201 with excellent in vitro and in vivo profile were selected as clinical candidates and are currently in phase 1 clinical development. This short review article provides a summary of the program history, the applied pharmacophore model and the discovery story of these novel p53-MDM2 inhibitor investigational drugs.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Clinical trial</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hdm2</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Inhibitor</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Mdm2</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nvp-cgm097</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nvp-hdm201</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Chemistry</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">CHIMIA</subfield><subfield code="d">Swiss Chemical Society, 2020</subfield><subfield code="g">71(2017), 10</subfield><subfield code="w">(DE-627)480660301</subfield><subfield code="w">(DE-600)2179192-2</subfield><subfield code="x">26732424</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:71</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.2533/chimia.2017.716</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/1e830f523fe54d70b46c9def3403fa01</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.chimia.ch/chimia/article/view/1668</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0009-4293</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2673-2424</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">71</subfield><subfield code="j">2017</subfield><subfield code="e">10</subfield></datafield></record></collection>
callnumber-first	Q - Science
author	Philipp Holzer
spellingShingle	Philipp Holzer misc QD1-999 misc Clinical trial misc Hdm2 misc Inhibitor misc Mdm2 misc Nvp-cgm097 misc Nvp-hdm201 misc Chemistry Discovery of Potent and Selective p53-MDM2 Protein–Protein Interaction Inhibitors as Anticancer Drugs
authorStr	Philipp Holzer
ppnlink_with_tag_str_mv	@@773@@(DE-627)480660301
format	electronic Article
delete_txt_mv	keep
author_role	aut
collection	DOAJ
remote_str	true
callnumber-label	QD1-999
illustrated	Not Illustrated
issn	26732424
topic_title	QD1-999 Discovery of Potent and Selective p53-MDM2 Protein–Protein Interaction Inhibitors as Anticancer Drugs Clinical trial Hdm2 Inhibitor Mdm2 Nvp-cgm097 Nvp-hdm201
topic	misc QD1-999 misc Clinical trial misc Hdm2 misc Inhibitor misc Mdm2 misc Nvp-cgm097 misc Nvp-hdm201 misc Chemistry
topic_unstemmed	misc QD1-999 misc Clinical trial misc Hdm2 misc Inhibitor misc Mdm2 misc Nvp-cgm097 misc Nvp-hdm201 misc Chemistry
topic_browse	misc QD1-999 misc Clinical trial misc Hdm2 misc Inhibitor misc Mdm2 misc Nvp-cgm097 misc Nvp-hdm201 misc Chemistry
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	CHIMIA
hierarchy_parent_id	480660301
hierarchy_top_title	CHIMIA
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)480660301 (DE-600)2179192-2
title	Discovery of Potent and Selective p53-MDM2 Protein–Protein Interaction Inhibitors as Anticancer Drugs
ctrlnum	(DE-627)DOAJ046037047 (DE-599)DOAJ1e830f523fe54d70b46c9def3403fa01
title_full	Discovery of Potent and Selective p53-MDM2 Protein–Protein Interaction Inhibitors as Anticancer Drugs
author_sort	Philipp Holzer
journal	CHIMIA
journalStr	CHIMIA
callnumber-first-code	Q
lang_code	ger eng fre
isOA_bool	true
recordtype	marc
publishDateSort	2017
contenttype_str_mv	txt
author_browse	Philipp Holzer
container_volume	71
class	QD1-999
format_se	Elektronische Aufsätze
author-letter	Philipp Holzer
doi_str_mv	10.2533/chimia.2017.716
title_sort	discovery of potent and selective p53-mdm2 protein–protein interaction inhibitors as anticancer drugs
callnumber	QD1-999
title_auth	Discovery of Potent and Selective p53-MDM2 Protein–Protein Interaction Inhibitors as Anticancer Drugs
abstract	As a result of our persistent efforts to discover novel inhibitors of the p53-MDM2 protein–protein interaction useful for the treatment of cancer, the potent and selective MDM2 inhibitors NVP-CGM097 and NVP-HDM201 with excellent in vitro and in vivo profile were selected as clinical candidates and are currently in phase 1 clinical development. This short review article provides a summary of the program history, the applied pharmacophore model and the discovery story of these novel p53-MDM2 inhibitor investigational drugs.
abstractGer	As a result of our persistent efforts to discover novel inhibitors of the p53-MDM2 protein–protein interaction useful for the treatment of cancer, the potent and selective MDM2 inhibitors NVP-CGM097 and NVP-HDM201 with excellent in vitro and in vivo profile were selected as clinical candidates and are currently in phase 1 clinical development. This short review article provides a summary of the program history, the applied pharmacophore model and the discovery story of these novel p53-MDM2 inhibitor investigational drugs.
abstract_unstemmed	As a result of our persistent efforts to discover novel inhibitors of the p53-MDM2 protein–protein interaction useful for the treatment of cancer, the potent and selective MDM2 inhibitors NVP-CGM097 and NVP-HDM201 with excellent in vitro and in vivo profile were selected as clinical candidates and are currently in phase 1 clinical development. This short review article provides a summary of the program history, the applied pharmacophore model and the discovery story of these novel p53-MDM2 inhibitor investigational drugs.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	10
title_short	Discovery of Potent and Selective p53-MDM2 Protein–Protein Interaction Inhibitors as Anticancer Drugs
url	https://doi.org/10.2533/chimia.2017.716 https://doaj.org/article/1e830f523fe54d70b46c9def3403fa01 https://www.chimia.ch/chimia/article/view/1668 https://doaj.org/toc/0009-4293 https://doaj.org/toc/2673-2424
remote_bool	true
ppnlink	480660301
callnumber-subject	QD - Chemistry
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.2533/chimia.2017.716
callnumber-a	QD1-999
up_date	2024-07-03T18:25:47.371Z
_version_	1803583380389888000
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ046037047</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308102142.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2017 xx \|\|\|\|\|o 00\| \|\|ger c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2533/chimia.2017.716</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ046037047</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ1e830f523fe54d70b46c9def3403fa01</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">ger</subfield><subfield code="a">eng</subfield><subfield code="a">fre</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QD1-999</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Philipp Holzer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Discovery of Potent and Selective p53-MDM2 Protein–Protein Interaction Inhibitors as Anticancer Drugs</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">As a result of our persistent efforts to discover novel inhibitors of the p53-MDM2 protein–protein interaction useful for the treatment of cancer, the potent and selective MDM2 inhibitors NVP-CGM097 and NVP-HDM201 with excellent in vitro and in vivo profile were selected as clinical candidates and are currently in phase 1 clinical development. This short review article provides a summary of the program history, the applied pharmacophore model and the discovery story of these novel p53-MDM2 inhibitor investigational drugs.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Clinical trial</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hdm2</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Inhibitor</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Mdm2</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nvp-cgm097</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Nvp-hdm201</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Chemistry</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">CHIMIA</subfield><subfield code="d">Swiss Chemical Society, 2020</subfield><subfield code="g">71(2017), 10</subfield><subfield code="w">(DE-627)480660301</subfield><subfield code="w">(DE-600)2179192-2</subfield><subfield code="x">26732424</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:71</subfield><subfield code="g">year:2017</subfield><subfield code="g">number:10</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.2533/chimia.2017.716</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/1e830f523fe54d70b46c9def3403fa01</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.chimia.ch/chimia/article/view/1668</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/0009-4293</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2673-2424</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">71</subfield><subfield code="j">2017</subfield><subfield code="e">10</subfield></datafield></record></collection>
score	7.400529

Nicht das Richtige dabei?

Schreiben Sie uns!

Discovery of Potent and Selective p53-MDM2 Protein–Protein Interaction Inhibitors as Anticancer Drugs

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?